China Research for Severe Spontaneous Intracerebral Hemorrhage(CRISIH)
NCT05975398 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000
Last updated 2026-07-10
Summary
Background: Although emergency surgery may reduce mortality in patients with severe spontaneous intracerebral hemorrhage (SSICH), the effectiveness and safety of surgical treatment among SSICH patients receiving long-term oral antiplatelet therapy (LOAPT) remain unclear. The CRISIH registry was originally designed to evaluate the effect and safety of emergency surgery in SSICH patients receiving LOAPT and has subsequently continued as an ongoing multicenter registry of spontaneous intracerebral hemorrhage.
Methods: The CRISIH registry is an ongoing prospective, multicenter cohort registry conducted across participating clinical centers in China. The registry was initiated in November 2019 and is designed as a 10-year registry with continued recruitment and follow-up. Data from the initial five-year enrollment period are used for interim and secondary analyses, while recruitment and follow-up continue during the subsequent registry period. Clinical, radiological, surgical, laboratory, and follow-up information are collected using standardized case report forms. For the originally registered primary outcome, patients are followed until death or 6 months after the occurrence of primary hemorrhage; selected follow-up assessments and secondary analyses may extend beyond this period according to the registry protocol.
Study Design: The CRISIH registry was designed as a prospective, multicenter cohort registry of patients with spontaneous intracerebral hemorrhage. One originally registered comparative focus evaluates SSICH patients receiving LOAPT, comparing total mortality and survival outcomes between patients receiving emergency surgical treatment and those receiving conservative treatment. The safety of surgery is assessed by comparing postoperative hemorrhagic complications among operated patients with and without LOAPT. Based on the observed clinical characteristics and outcomes of patients receiving LOAPT, the registry also evaluates ischemic events after discontinuation of LOAPT and explores coagulation function assessment strategies in operated patients receiving LOAPT.
Objective: The CRISIH registry aims to prospectively evaluate clinical outcomes and management strategies in patients with spontaneous intracerebral hemorrhage. An originally registered focus of the registry is to assess the effectiveness and safety of emergency surgery among SSICH patients receiving LOAPT, thereby generating evidence to support future clinical management.
Secondary Analysis Update: The present update describes an interim secondary analysis of the ongoing CRISIH registry based on patients enrolled during the initial five-year period from November 2019 to December 2024. This analysis focuses on postoperative disorders of consciousness after surgery for spontaneous intracerebral hemorrhage, with consciousness status assessed at 30, 90, 180, and 365 days after surgery using the Coma Recovery Scale-Revised. This interim secondary analysis does not alter the ongoing registry design, recruitment status, or originally registered primary outcome.
Conditions
- Severe Spontaneous Intracranial Hemorrhage
- Long-term Antiplatelet Treatment
- Emergency Surgery
- Complications
- Disorders of Consciousness
Interventions
- PROCEDURE
-
Emergency neurosurgery
Surgical evacuation for intracerebral hemorrhage
- PROCEDURE
-
Conservative treatment
Standard treatment for intracerebral hemorrhage
Sponsors & Collaborators
-
Beijing Chao Yang Hospital
collaborator OTHER -
Beijing Shuyi Hospital
collaborator OTHER -
Beijing Anzhen Hospital
collaborator OTHER -
Guangzhou Red Cross Hospital
collaborator OTHER -
Beijing Pinggu District Hospital
collaborator OTHER -
Beijing Friendship Hospital
collaborator OTHER -
Wuxi No. 2 People's Hospital
collaborator OTHER -
Dezhou People's Hospital
collaborator OTHER -
Binzhou People's Hospital
collaborator OTHER -
First Affiliated Hospital of Fujian Medical University
collaborator OTHER -
Anxi County Hospital
collaborator UNKNOWN -
Datong People's Hospital
collaborator UNKNOWN -
Shijiazhuang Third Hospital
collaborator UNKNOWN -
Qingyuan People's Hospital
collaborator OTHER -
Jingzhou Central Hospital
collaborator OTHER -
Jiuquan City People's Hospital
collaborator UNKNOWN -
Zhoukou People's Hospital
collaborator UNKNOWN -
Jincheng People's Hospital
collaborator OTHER -
The First Affiliated Hospital of Zhengzhou University
collaborator OTHER -
Xinyu People's Hospital
collaborator UNKNOWN -
Beijing Tiantan Hospital
lead OTHER
Principal Investigators
-
Shuo Wang · Beijing Tiantan Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-11-01
- Primary Completion
- 2029-12-30
- Completion
- 2030-12-31
Countries
- China
Study Locations
More Related Trials
-
Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage
NCT02367248 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Appropriateness of Methodist Health System(MHS) Inter-facility Transfers of Traumatic Intracranial Subarachnoid Hemorrhage and Spontaneous Bleeds for Level-1 Advanced Surgical Intervention
NCT06136078 ·Status: RECRUITING
-
China Antihypertensive Trial for Intracranial Aneurysm
NCT05941377 ·Status: COMPLETED ·Phase: NA
-
Multimodal Monitoring in Patients With Spontaneous Intracerebral Hemorrhage
NCT02326571 ·Status: COMPLETED
-
The Treatment Effect of Endoscopic Evacuation Versus Suboccipital Craniotomy for Spontaneous Intracerebellar Hemorrhage.
NCT04991233 ·Status: UNKNOWN ·Phase: NA
-
Analgesia-first Minimal Sedation for Spontaneous Intracerebral Hemorrhage Early Antihypertensive Treatment
NCT03207100 ·Status: COMPLETED ·Phase: NA
-
Osmotic Therapy for Patients With Severe Subarachnoid Hemorrhage
NCT05858060 ·Status: RECRUITING
-
Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury
NCT03035838 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Neurological Outcome in Patients of Traumatic Subarachnoid Haemorrhage
NCT02073890 ·Status: COMPLETED
-
Effects of Head-of-Bed on Intracranial Pressure
NCT05604404 ·Status: WITHDRAWN ·Phase: NA
-
Management and Outcomes Following Emergency Surgery for Traumatic Brain Injury
NCT04212754 ·Status: UNKNOWN
-
Hidden Impairments During Subarachnoid Haemorrhage Recovery, Description and Evolution of a Newly Described Syndrom
NCT06276517 ·Status: WITHDRAWN
-
Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury
NCT01810276 ·Status: TERMINATED ·Phase: NA
-
Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial Aneurysms
NCT04532333 ·Status: UNKNOWN ·Phase: PHASE3
-
Blind Versus Targeted Epidural Patch With Autologous Platelet-rich Plasma for Spontaneous Intracranial Hypotension
NCT07283536 ·Status: WITHDRAWN ·Phase: NA
-
Early Blood Pressure Intervention After Coiling or Clipping for Subarachnoid Hemorrhage
NCT07149922 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Severe Head Injury Brain Analysis
NCT05206760 ·Status: COMPLETED
-
Mannitol vs HS to Treat ICHT After Severe TBI : Comparison on PtiO2 and Microdialysis Values
NCT01028339 ·Status: TERMINATED ·Phase: PHASE3
-
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
NCT00124293 ·Status: COMPLETED
-
NIRS Directed Optimal Cerebral Perfusion Pressure in Aneurysmal Subarachnoid Hemorrhage Patients: A Feasibility Study
NCT03879330 ·Status: UNKNOWN
-
Clinical Study on the Treatment of Hypertensive Intracerebral Hemorrhage With Panax Notoginseng Saponin
NCT02999048 ·Status: COMPLETED ·Phase: PHASE4
-
The Optimal Dose of Mannitol for Intraoperative Brain Relaxation During the Operation of Aneurysmal Subarachnoid Hemorrhage
NCT04135456 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Geriatric Head Trauma Short Term Outcomes Project
NCT04044924 ·Status: COMPLETED
-
Systemic Normothermia in Intracerebral Hemorrhage (ICH)
NCT02078037 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Neuroprotectant for Hypertensive Intracerebral Hemorrhage
NCT03546283 ·Status: UNKNOWN ·Phase: PHASE3